82 research outputs found
Drotrecogin alpha: a rational approach to the treatment of submassive pulmonary embolism?
Combining therapeutic doses of low-molecular-weight heparins and increasing doses of recombinant activated protein C - Drotrecogin alpha (activated), or DAA - is of theoretical interest with regard to the control of coagulation activation. The study by Dempfle and colleagues presents new data showing that endogenous activated protein C levels do not increase in nonseptic patients with pulmonary embolism. However, the results of the addition of these two treatments are puzzling, leaving unresolved the questionable clinical relevance of this combination and the possible increase in bleeding risk
Antiplatelet therapy in atherothrombotic diseases : similarities and differences across guidelines
Antiplatelet therapy, mainly consisting of aspirin and P2Y12 receptor antagonists, is the
cornerstone of the pharmacological treatment and prevention of atherothrombotic
diseases. Its use, especially in secondary cardiovascular prevention, has significantly
improved patient clinical outcomes in the last decades. Primary safety endpoint
(i.e., bleeding complications) remain a major drawback of antiplatelet drugs. National
and international societies have published and regularly updated guidelines for antiplatelet
therapy aiming to provide clinicians with practical recommendations for a better handling of
these drugs in various clinical settings. Many recommendations find common ground
between international guidelines, but certain strategies vary across the countries,
particularly with regard to the choice of molecules, dosage, and treatment duration. In
this review, we detail and discuss the main antiplatelet therapy indications in the light of the
different published guidelines and the significant number of recently published clinical trials
and meta-analyses and highlight the areas that deserve further investigation in order to
improve antiplatelet therapy in patients with atherothrombotic diseases
Extracorporeal Membrane Oxygenation for Severe Acute Respiratory Distress Syndrome associated with COVID-19: An Emulated Target Trial Analysis.
RATIONALE: Whether COVID patients may benefit from extracorporeal membrane oxygenation (ECMO) compared with conventional invasive mechanical ventilation (IMV) remains unknown. OBJECTIVES: To estimate the effect of ECMO on 90-Day mortality vs IMV only Methods: Among 4,244 critically ill adult patients with COVID-19 included in a multicenter cohort study, we emulated a target trial comparing the treatment strategies of initiating ECMO vs. no ECMO within 7 days of IMV in patients with severe acute respiratory distress syndrome (PaO2/FiO2 <80 or PaCO2 ≥60 mmHg). We controlled for confounding using a multivariable Cox model based on predefined variables. MAIN RESULTS: 1,235 patients met the full eligibility criteria for the emulated trial, among whom 164 patients initiated ECMO. The ECMO strategy had a higher survival probability at Day-7 from the onset of eligibility criteria (87% vs 83%, risk difference: 4%, 95% CI 0;9%) which decreased during follow-up (survival at Day-90: 63% vs 65%, risk difference: -2%, 95% CI -10;5%). However, ECMO was associated with higher survival when performed in high-volume ECMO centers or in regions where a specific ECMO network organization was set up to handle high demand, and when initiated within the first 4 days of MV and in profoundly hypoxemic patients. CONCLUSIONS: In an emulated trial based on a nationwide COVID-19 cohort, we found differential survival over time of an ECMO compared with a no-ECMO strategy. However, ECMO was consistently associated with better outcomes when performed in high-volume centers and in regions with ECMO capacities specifically organized to handle high demand. This article is open access and distributed under the terms of the Creative Commons Attribution Non-Commercial No Derivatives License 4.0 (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Gestion des agents antiplaquettaires pour une procédure invasive programmée: propositions du groupe d'intérêt en hémostase périopératoire (GIHP) et du groupe français d’études sur l'hemostase et la thrombose (GFHT) en collaboration avec la Société française d'anesthesie-réanimation (SFAR)
0SCOPUS: re.jinfo:eu-repo/semantics/publishe
Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR)
The French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Haemostasis and Thrombosis (GFHT) in collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR) drafted up-to-date proposals for the management of antiplatelet therapy in patients undergoing elective invasive procedures. The proposals were discussed and validated by a vote; all proposals but one could be assigned with a high strength. The management of antiplatelet therapy is based on their indication and the procedure. The risk of bleeding related to the procedure can be divided into high, moderate and low categories depending on the possibility of performing the procedure in patients receiving antiplatelet agents (none, monotherapy and dual antiplatelet therapy respectively). If discontinuation of antiplatelet therapy is indicated before the procedure, a last intake of aspirin, clopidogrel, ticagrelor and prasugrel 3, 5, 5 and 7 days before surgery respectively is proposed. The thrombotic risk associated with discontinuation should be assessed according to each specific indication of antiplatelet therapy and is higher for patients receiving dual therapy for coronary artery disease (with further refinements based on a few well-accepted items) than for those receiving monotherapy for cardiovascular prevention, for secondary stroke prevention or for lower extremity arterial disease. These proposals also address the issue of the potential role of platelet functional tests and consider management of antiplatelet therapy for regional anaesthesia, including central neuraxial anaesthesia and peripheral nerve blocks, and for coronary artery surgery.SCOPUS: ar.jinfo:eu-repo/semantics/publishe
Evaluation d'agents pro-hemostatiques pour l'antagonisation des molécules anticoagulantes anti-xa dans un modèle de thrombose et de saignement chez le lapin
PARIS7-Bibliothèque centrale (751132105) / SudocSudocFranceF
Influence de l'injection de produit de contraste iodé chez les patients donneurs de reins cadavériques sur la survie du greffon
PARIS6-Bibl. St Antoine CHU (751122104) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF
- …